Excipients Used for Solid Dosage: Innovations and Challenges

Solid dosage forms are cornerstones of pharmaceutical delivery systems. Their widespread preference among patients and healthcare providers is highlighted by their ease of administration, dosage accuracy, and cost-effectiveness. However, the effectiveness of these solid dosage forms is not determined solely by their active pharmaceutical ingredients (APIs). Pharmaceutical excipients, the substances formulated alongside the active ingredients, play a critical role in creating efficient, stable, and patient-friendly medications.

Excipients are far from mere fillers or inactive bystanders; they enhance therapeutic efficacy, modify drug release, ensure stability, and improve the palatability of medications. Their role is essential in the manufacturing process, affecting the product’s overall performance and acceptability.

Moreover, as drug development evolves, the role of excipients becomes increasingly complex and pivotal. Innovations in excipient technology have opened new avenues for addressing formulation challenges associated with novel and highly potent APIs. The pharmaceutical industry’s journey towards more sophisticated drug delivery mechanisms continues to spotlight the indispensable nature of excipients.

This article will explore excipients’ multifaceted roles in solid dosage forms, highlighting technological advancement and current challenges while incorporating insights from interviews with industry professionals across the pharmaceutical manufacturing spectrum. Through this exploration, we will uncover how modern excipients set the stage for future drug delivery and patient care innovations.

Advances in Excipient Technology

The pharmaceutical excipients industry has seen remarkable technological advancements in recent years, primarily aimed at enhancing drug formulation capabilities and addressing specific challenges associated with the delivery of APIs. These innovations are pivotal in improving drug efficacy, safety, and patient compliance, thereby playing a critical role in the success of pharmaceutical products.

Global Business Manager at Colorcon, Russell Prestipino, gives us his thoughts: “The ultimate value that these new technologies provide is to improve the quality and efficacy of products that patients receive. Often, it is the interplay of the excipient with the APIs driving this improvement with a newer technology. How can we increase the bioavailability of an active while also reducing the size of the dosage form? Can the manufacturing process be more efficient, and can we make drug products on more of an at-time-of-need basis? Both questions are enabled by advancements in technology yet are not a reality without specific quality attributes offered by the excipient.”

Enhancing Drug Solubility

One of the most pressing issues in pharmaceutical development is the poor water solubility of many new chemical entities. Chandan Kaiwar, Product Manager at Kerry gives the following examples of ways that excipients contribute to improving the solubility and bioavailability of pharmaceutical products:

• Solubilization: Excipients such as surfactants and co-solvents enhance drug solubility by forming micelles or solubilizing drug molecules.
• Particle size reduction: Excipients like polymers or surfactants reduce drug particle size, increasing the surface area available for dissolution and absorption.
• Complexation:  Excipients like cyclodextrins form inclusion complexes with poorly soluble drugs, improving their solubility and dissolution rate.
• Amorphous solid dispersion:  Excipients like polymers formulate amorphous solid dispersions, preventing drug crystallization and promoting rapid dissolution.
• pH modification: Excipients like buffering agents alter gastrointestinal pH, optimizing drug solubility and absorption at specific sites.

Co-Processed Excipients

Co-processed excipients represent a significant advancement in pharmaceutical formulation technology, designed to address the limitations of traditional excipients while optimizing the manufacturing process and enhancing drug product performance. These are composite particles formed by physically processing two or more excipients to obtain a product with better characteristics than the simple physical mixture of their individual components.

The primary advantage of using co-processed excipients lies in their ability to enhance the functionality of a formulation. They can improve compressibility, enhance flow properties, and optimize the dissolution profile of the API. For instance, a co-processed product combining a super-disintegrant and a filler might exhibit superior tablet disintegration rates without compromising the tablet’s hardness or integrity, thereby enhancing the onset of action of the API.

“We are seeing a lot of interest in co-processed excipients (CPEs), due to the multiple benefits they provide to manufacturers, such as increased manufacturing efficiency.” Says John Gilligan, Senior Business Manager at Innophos, “CPEs often reduce the number of ingredients needed in a formulation, resulting in lower inventory levels, fewer quality control checks and approvals, and decreased batching times. In addition, performance benefits such as improved tablet integrity, compression, and ejection profiles can be realized. With fewer ingredients, labels are cleaner, and tablets are often smaller, which consumers prefer.”

Overall, the continual evolution of excipient technology broadens the scope of treatable conditions and significantly influences the cost-effectiveness of therapies. Insights from industry professionals like Russell Prestipino, Chandan Kaiwar, and John Gilligan underscore the transformative impact of these technologies, not just in terms of enhancing drug performance but also in streamlining production processes.

Current Challenges

While excipient technology has made significant strides in recent years, several challenges persist, requiring ongoing research and innovation to overcome them. These challenges span various aspects of formulation development, manufacturing, regulatory compliance, and market demands.

Stability Concerns

Maintaining the stability of pharmaceutical formulations over their shelf life is crucial for ensuring product efficacy and safety. Excipients can influence the stability of APIs through various mechanisms, including degradation reactions, moisture absorption, and physical interactions. Formulators must conduct rigorous stability testing to identify potential stability challenges and optimize formulation compositions accordingly.

Regulatory Compliance

The regulatory landscape governing excipients is complex and continually evolving. Regulatory agencies impose stringent requirements on excipient quality, safety, and documentation. Compliance with regulatory guidelines is essential for market approval and commercialization, adding complexity to the formulation and development process.

“The regulatory challenges faced by the pharma industry tend to mirror the concerns faced by excipient manufacturers.” Says Russell Prestipino, Global Business Manager at Colorcon, “Current hot topics include nitrosamines, DEG/EG testing, titanium dioxide alternatives, and the use of novel excipients. These types of challenges call for a strong partnership between the pharmaceutical manufacturers and their excipient suppliers that includes open information sharing in support of these and other emerging topics. Providing this type of information quickly can be challenging for manufacturers that serve various markets, especially where the pharma industry is only a small sector of their overall business. Excipient manufacturers that focus primarily on the pharma industry are generally well suited to keep abreast of emerging issues facing pharma and prepare accordingly to support their customer’s ever-growing need for more and more information on the materials they use in their formulations.”

Cost and Supply Chain Management

Excipient costs can constitute a significant portion of overall manufacturing expenses, particularly for high-volume products. Formulators must balance cost considerations with the need for high-quality excipients that meet regulatory standards.

Chandan Kaiwar, Product Manager at Kerry, weighs in about supply chain issues and trends that are impacting the use of excipients in the production of pharmaceuticals:

• Raw material sourcing:  Challenges in availability, quality, and cost influenced by geopolitical tensions and market fluctuations.
• Regulatory compliance:  Stringent requirements for excipient manufacturing, transportation, and storage, necessitating adherence to GMP and international standards.
• Quality assurance:  Ensuring integrity and purity throughout the supply chain to maintain product safety and quality standards.
• Globalization: Complexities in logistics, compliance, and quality control due to the global nature of excipient sourcing and production.
• Supply chain resilience: Focus on building resilient supply chains capable of withstanding disruptions through strategies like dual sourcing and risk mitigation measures.
• Sustainability:  Emphasis on sustainable practices, including eco-friendly processes and renewable resources, driven by environmental concerns and regulatory pressures.

Safety and Efficacy

Excipients play a crucial role in drug formulations, contributing to pharmaceutical products’ safety, efficacy, and overall performance. However, ensuring the safety and efficacy of excipients is vital to the development and regulatory approval of medications.

Brian Kirkland, Regulatory Affairs Manager at Innophos, offers some advice to ensure the safety and efficacy of excipients used in drug formulations, “Pharmaceutical companies should identify appropriate regulatory and GMP requirements based on their product’s intended use. Companies need to obtain information about the excipient manufacturer, the distributor, and the excipient itself as part of their supplier and excipient qualification process. Pharmaceutical companies can meet the expectation by doing one of the following:

• Partner with a supplier that uses a third-party auditing service and is certified under an audit scheme such as BRC, ISO 22,000, or SQF
• Doing their audits
• Using an independent third-party certification body to conduct an onsite inspection of excipient suppliers and their overall supply chain.

In conclusion, the landscape of solid dosage formulations relies heavily on the symbiotic relationship between APIs and excipients. Excipients are not passive ingredients but active contributors to the formulation’s success, influencing drug release kinetics, solubility enhancement, and overall drug performance. As drug development progresses, the demand for excipients that can meet the challenges posed by novel APIs grows, pushing the boundaries of excipient technology.

However, these advancements are not without their hurdles. Challenges such as stability concerns, regulatory compliance, and supply chain management continue to pose significant obstacles. The need for excipients that meet regulatory standards and adhere to evolving market demands requires a delicate balance of innovation and adherence to stringent quality controls.

Addressing these challenges demands collaboration and transparency across the pharmaceutical industry. Regulatory agencies, excipient suppliers, and pharmaceutical manufacturers must work together to ensure the safety, efficacy, and quality of excipient-based formulations.

By embracing technological advancements and overcoming challenges, the excipient industry will continue to play a pivotal role in shaping the future of pharmaceutical formulations and improving global healthcare.

Publication Details